NovalGen

NovalGen's first pipeline product is a patented bispecific T-cell therapy capable of safely harnessing the immune system to combat various cancers. The company’s lead project is based on a novel receptor-targeting system that activates T-cells, enabling us to target both hematologic malignancies and solid tumors. Our programs span a range of medical applications and address different objectives, including blood cancers, solid tumors, autoimmune diseases, hematological disorders, and difficult-to-treat infections. One of the biggest challenges in treating cancer and other diseases is finding therapies with the fewest side effects and the highest cost-effectiveness.